HRP20230605T1 - Protutijela protiv interferona beta i njihova upotreba - Google Patents
Protutijela protiv interferona beta i njihova upotreba Download PDFInfo
- Publication number
- HRP20230605T1 HRP20230605T1 HRP20230605TT HRP20230605T HRP20230605T1 HR P20230605 T1 HRP20230605 T1 HR P20230605T1 HR P20230605T T HRP20230605T T HR P20230605TT HR P20230605 T HRP20230605 T HR P20230605T HR P20230605 T1 HRP20230605 T1 HR P20230605T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- antibody
- fragment
- binds
- nucleic acid
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title 1
- 108090000467 Interferon-beta Proteins 0.000 title 1
- 229960001388 interferon-beta Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (10)
1. Izolirano protutijelo, ili njegov fragment koji se veže na antigen, koji se specifično veže na ljudski IFNβ, naznačeno time što sadrži VH koji sadrži aminokiselinski slijed SEQ ID NO: 28 i VL koji sadrži aminokiselinski slijed SEQ ID NO: 1.
2. Izolirana molekula nukleinske kiseline, naznačena time što sadrži nukleotidni slijed koji kodira protutijelo, ili njegov fragment koji se veže na antigen, u skladu s patentnim zahtjevom 1.
3. Izolirana molekula nukleinske kiseline u skladu s patentnim zahtjevom 2, naznačena time što sadrži nukleotidni slijed SEQ ID NO:166 i SEQ ID NO:167.
4. Izolirana molekula nukleinske kiseline u skladu s patentnim zahtjevom 2, naznačena time što sadrži nukleotidni slijed umetka plazmida deponiranog kod ATCC, s pristupnim brojem PTA-122726, i nukleotidni slijed umetka plazmida deponiranog kod ATCC, s pristupnim brojem PTA-122727.
5. Vektor, naznačen time što sadrži molekulu nukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 2 do 4.
6. Stanica domaćin, naznačena time što sadrži molekulu nukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 2 do 4, ili vektor u skladu s patentnim zahtjevom 5.
7. Postupak proizvodnje protutijela, ili njegovog fragmenta koji se veže na antigen, naznačen time što se sastoji u uzgoju stanice domaćina u skladu s patentnim zahtjevom 6, u uvjetima u kojima stanica domaćin proizvodi protutijelo, ili njegov fragment koji se veže na antigen.
8. Farmaceutski pripravak, naznačen time što sadrži protutijelo, ili njegov fragment koji se veže na antigen, u skladu s patentnim zahtjevom 1, kao i farmaceutski prihvatljivo pomoćno sredstvo.
9. Protutijelo, ili njegov fragment koji se veže na antigen, u skladu s patentnim zahtjevom 1, ili farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačeni time što su namijenjeni upotrebi u terapiji.
10. Protutijelo, ili njegov fragment koji se veže na antigen, u skladu s patentnim zahtjevom 1, ili farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačeni time što su namijenjeni upotrebi u postupku liječenja dermatomiozitisa (DM) ili u postupku liječenja sistemnog eritemskog lupusa (SLE).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329327P | 2016-04-29 | 2016-04-29 | |
| US201662339709P | 2016-05-20 | 2016-05-20 | |
| US201762483669P | 2017-04-10 | 2017-04-10 | |
| PCT/US2017/030089 WO2017189983A1 (en) | 2016-04-29 | 2017-04-28 | Interferon beta antibodies and uses thereof |
| EP17733171.7A EP3448419B1 (en) | 2016-04-29 | 2017-04-28 | Interferon beta antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230605T1 true HRP20230605T1 (hr) | 2023-09-29 |
Family
ID=59215947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230605TT HRP20230605T1 (hr) | 2016-04-29 | 2017-04-28 | Protutijela protiv interferona beta i njihova upotreba |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10829553B2 (hr) |
| EP (2) | EP3448419B1 (hr) |
| JP (2) | JP6799076B2 (hr) |
| KR (1) | KR102527840B1 (hr) |
| CN (1) | CN109069606B (hr) |
| AU (1) | AU2017258492B2 (hr) |
| BR (1) | BR112018072118A2 (hr) |
| CA (1) | CA2965652A1 (hr) |
| CO (1) | CO2018012497A2 (hr) |
| DK (1) | DK3448419T3 (hr) |
| ES (1) | ES2950288T3 (hr) |
| FI (1) | FI3448419T3 (hr) |
| HR (1) | HRP20230605T1 (hr) |
| HU (1) | HUE063621T2 (hr) |
| IL (1) | IL262244B2 (hr) |
| MX (1) | MX2018013222A (hr) |
| MY (1) | MY194084A (hr) |
| NZ (1) | NZ747225A (hr) |
| PE (1) | PE20190371A1 (hr) |
| PH (1) | PH12018502275A1 (hr) |
| PL (1) | PL3448419T3 (hr) |
| PT (1) | PT3448419T (hr) |
| RU (1) | RU2750454C2 (hr) |
| SA (1) | SA518400327B1 (hr) |
| SG (1) | SG11201809456UA (hr) |
| SI (1) | SI3448419T1 (hr) |
| TW (1) | TWI776808B (hr) |
| WO (1) | WO2017189983A1 (hr) |
| ZA (1) | ZA201806682B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2950288T3 (es) | 2016-04-29 | 2023-10-06 | Pfizer | Anticuerpos interferón beta y usos de los mismos |
| WO2019040674A1 (en) | 2017-08-22 | 2019-02-28 | Sanabio, Llc | SOLUBLE INTERFERON RECEPTORS AND USES THEREOF |
| CA3098374A1 (en) | 2018-04-25 | 2019-10-31 | Prometheus Biosciences, Inc. | Optimized anti-tl1a antibodies |
| US20220144957A1 (en) * | 2019-01-31 | 2022-05-12 | Immunecent Biotechnology, Inc. | Novel anti-ifnar1 antibodies |
| IL292419A (en) | 2019-10-24 | 2022-06-01 | Prometheus Biosciences Inc | Human antibodies to TNF-like ligand 1a (tl1a) and uses thereof |
| CN114733455B (zh) * | 2022-04-15 | 2023-02-14 | 北京田园奥瑞生物科技有限公司 | 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物***分型的方法 |
| WO2024062420A1 (en) * | 2022-09-22 | 2024-03-28 | Pfizer Inc. | METHODS OF TREATMENT WITH IFNß ANTIBODIES |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6682896B1 (en) * | 1988-10-14 | 2004-01-27 | Schering Aktiengesellschaft | Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof |
| JP2717319B2 (ja) * | 1988-10-14 | 1998-02-18 | ベルレックス、ラボラトリーズ、インコーポレイテッド | Ｒ―ｉｆｎ―ベータエピトープ部位を代表するペプチド、それに対する抗体、およびその用途 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL108584A (en) | 1994-02-07 | 2008-03-20 | Yeda Res & Dev | Cloning of the interferon-binding protein ALPHA / BETA |
| ZA9811070B (en) * | 1997-12-08 | 2000-07-03 | Genentech Inc | Type I interferons. |
| JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| SI2263692T1 (sl) | 2002-12-24 | 2020-10-30 | Rinat Neuroscience Corp. | Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo |
| WO2012138975A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
| CN102898521A (zh) * | 2011-07-26 | 2013-01-30 | 上海市免疫学研究所 | 抗β-干扰素单克隆抗体及其应用 |
| US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| BR112017027578A2 (pt) | 2015-06-26 | 2018-08-28 | Bioverativ Usa Inc | métodos de tratamento de distúrbios autoimunes e aloimunes |
| ES2950288T3 (es) | 2016-04-29 | 2023-10-06 | Pfizer | Anticuerpos interferón beta y usos de los mismos |
-
2017
- 2017-04-28 ES ES17733171T patent/ES2950288T3/es active Active
- 2017-04-28 AU AU2017258492A patent/AU2017258492B2/en active Active
- 2017-04-28 MX MX2018013222A patent/MX2018013222A/es unknown
- 2017-04-28 SG SG11201809456UA patent/SG11201809456UA/en unknown
- 2017-04-28 FI FIEP17733171.7T patent/FI3448419T3/fi active
- 2017-04-28 RU RU2018141839A patent/RU2750454C2/ru active
- 2017-04-28 PE PE2018002056A patent/PE20190371A1/es unknown
- 2017-04-28 HR HRP20230605TT patent/HRP20230605T1/hr unknown
- 2017-04-28 PT PT177331717T patent/PT3448419T/pt unknown
- 2017-04-28 TW TW106114362A patent/TWI776808B/zh active
- 2017-04-28 PL PL17733171.7T patent/PL3448419T3/pl unknown
- 2017-04-28 WO PCT/US2017/030089 patent/WO2017189983A1/en active Application Filing
- 2017-04-28 US US15/581,079 patent/US10829553B2/en active Active
- 2017-04-28 BR BR112018072118-2A patent/BR112018072118A2/pt unknown
- 2017-04-28 JP JP2018556490A patent/JP6799076B2/ja active Active
- 2017-04-28 EP EP17733171.7A patent/EP3448419B1/en active Active
- 2017-04-28 CA CA2965652A patent/CA2965652A1/en active Pending
- 2017-04-28 KR KR1020187034153A patent/KR102527840B1/ko active IP Right Grant
- 2017-04-28 SI SI201731384T patent/SI3448419T1/sl unknown
- 2017-04-28 DK DK17733171.7T patent/DK3448419T3/da active
- 2017-04-28 MY MYPI2018703975A patent/MY194084A/en unknown
- 2017-04-28 NZ NZ747225A patent/NZ747225A/en unknown
- 2017-04-28 IL IL262244A patent/IL262244B2/en unknown
- 2017-04-28 EP EP23177086.8A patent/EP4273165A3/en active Pending
- 2017-04-28 CN CN201780025961.XA patent/CN109069606B/zh active Active
- 2017-04-28 HU HUE17733171A patent/HUE063621T2/hu unknown
-
2018
- 2018-10-08 ZA ZA2018/06682A patent/ZA201806682B/en unknown
- 2018-10-25 PH PH12018502275A patent/PH12018502275A1/en unknown
- 2018-10-28 SA SA518400327A patent/SA518400327B1/ar unknown
- 2018-11-21 CO CONC2018/0012497A patent/CO2018012497A2/es unknown
-
2020
- 2020-11-09 US US17/092,998 patent/US11858986B2/en active Active
- 2020-11-19 JP JP2020192541A patent/JP7102489B2/ja active Active
-
2023
- 2023-11-16 US US18/511,744 patent/US20240174742A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230605T1 (hr) | Protutijela protiv interferona beta i njihova upotreba | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20201852T1 (hr) | Optimizacija antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| JP2018535196A5 (hr) | ||
| JP2016196468A5 (hr) | ||
| JP2016026215A5 (hr) | ||
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2015143226A5 (hr) | ||
| JP2016053091A5 (hr) | ||
| IL278014B1 (en) | Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use | |
| JP2017531427A5 (hr) | ||
| JP2018521691A5 (hr) | ||
| FI3137504T3 (fi) | Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten | |
| WO2017218974A3 (en) | Treatment of amd using aav2 variant with aflibercept | |
| HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
| JP2019523221A5 (hr) | ||
| JP2012034692A5 (hr) | ||
| JP2013121353A5 (hr) | ||
| MX2023009050A (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. |